These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 32654458)

  • 1. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
    Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
    [No Abstract]   [Full Text] [Related]  

  • 2. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Characteristics and Prognostic Analysis of Extranodal NK/T-Cell Lymphoma Patients Treated with Pegaspargase Based Chemotherapy].
    Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):735-740. PubMed ID: 34105466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Extranodal NK/T-cell lymphoma, nasal type: a clinical analysis].
    Chen F; Shen CX; Wang HG; Li GX; Wang XQ; Wen Z
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Mar; 31(5):327-333. PubMed ID: 29871255
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma].
    Li QH; Yang P; Wang JJ; Dong F; Tian L; Wan W; Ke XY; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):86-90. PubMed ID: 33554802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
    Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
    Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.
    Zhao Q; Fan S; Chang Y; Liu X; Li W; Ma Q; Li Y; Wang Y; Zhang L; Zhang M
    Cancer Manag Res; 2019; 11():3555-3564. PubMed ID: 31118779
    [No Abstract]   [Full Text] [Related]  

  • 12. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
    Yuan FF; Yin QS; Fu YW; Wang Q; Chen L; Mi RH; Li YF; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):569-572. PubMed ID: 30122016
    [No Abstract]   [Full Text] [Related]  

  • 15. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
    Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
    Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
    Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
    Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.